Shares of Kazia Therapeutics (NASDAQ: KZIA) climbed 80% on Wednesday after the company announcednew preclinical data published in Molecular Cancer Therapeutics demonstrating that its lead…
June 11, 2025
April 04, 2025
Sangamo and Lilly Strike $1.4 Billion Gene Therapy Deal to Tackle Neurological Diseases
Sangamo Therapeutics (SGMO) announced a new licensing agreement with Eli Lilly that sent its shares up as much as 23% in premarket trading this morning,…
March 19, 2025
Black Diamond Therapeutics Shares Surge 32.14% After $780M Licensing Deal with Servier
Black Diamond Therapeutics (BDTX) has signed a global licensing agreement with Servier for its targeted oncology therapy, BDTX-4933, sparking a 32.14% surge in BDTX shares….
February 24, 2025
BioStem Receives Institutional Review Board (IRB) Approval to Advance Clinical Trial in Treatment of Venous Leg Ulcers
BioStem Technologies (BSEM) announced IRB approval for a clinical study evaluating its BioREtain® Amnion Chorion (BR-AC) technology for treating venous leg ulcers (VLU). The study…
February 24, 2025
PepGen Shares Trade Up 180% on Positive Results from FREEDON-DM1 Trial to Treat Myotonic Dystrophy Type 1
The clinical stage biotechnology company focused on the advancement of next generation of oligonucleotide therapies to treat severe neuromuscular and neurological diseases, PepGen Inc. (PEPG) announced…
January 30, 2025
MindMed Announces First Patient Dosed in Phase 3 of Panorama Study for Generalized Anxiety Disorder
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), a late-stage biopharmaceutical company, has announced the first patient dosing in Panorama, its second Phase 3 study of MM120…
December 13, 2024
Candel Prices $80 Million Public Offering; Shares Slide Following Surge on Positive Phase 3 Prostate Cancer Study Results
Candel Therapeutics, Inc. (NASDAQ: CNDL) announced the pricing of its $80 million underwritten public offering, which includes approximately 10 million shares at $6.00 per share…
Shares in psychedelic-derived therapeutics company, Clearmind Medicine (Nasdaq: CMND), surged on Monday after the company announced it will participate in the 2024 Psychedelic Medicine –…
July 09, 2024
CytoSorbents Receives Regulatory Approval of CytoSorb® in Taiwan ; Secures $20M Credit Facility
CytoSorbents Corporation (Nasdaq: CTSO) has secured regulatory approval from the Taiwan Food and Drug Administration (TFDA) for CytoSorb®, the company’s extracorporeal cytokine adsorber that reduces…
June 26, 2024
Stock to Watch: Lipella Pharmaceuticals Builds Value with Broad Pipeline of Promising Orphan Drugs
Clinical-stage biotechnology company, Lipella Pharmaceuticals (Nasdaq: LIPO) is building sustainable value for investors and setting itself apart through its strategic targeting of attractive addressable patient…
Shares in the women’s healthcare company, Agile Therapeutics (OTC: AGRX), surged by more than 320% in morning trading on Wednesday after the company announced it…
Antimicrobial resistance (AMR) is currently one of the greatest threats to public health globally. Eli Lilly (NYSE: LLY)has announced that it will collaborate with the…